Why the study?
It was unknown whether patients with AF demonstrate detectable changes in hsTnT, NT-proBNP, and GDF-15 over 12 months, and whether such changes relate to subsequent stroke or systemic embolic events and bleeding.
Are changes in biomarkers (hsTnT, NT-proBNP, GDF-15) over 12 months associated with the subsequent risk of stroke, systemic embolic events, and bleeding in patients with atrial fibrillation?
Are changes in biomarkers (hsTnT, NT-proBNP, GDF-15) over 12 months associated with the subsequent risk of stroke, systemic embolic events, and bleeding in patients with atrial fibrillation?
Serial assessment of hsTnT, NT-proBNP, and GDF-15 over 1 year reveals dynamic changes that are strongly associated with the subsequent risk of stroke, systemic embolism, and bleeding in anticoagulated patients with atrial fibrillation.
Answers are grounded in this paper and cite their sources.
May support serial biomarker monitoring to refine AF risk stratification; hypothesis-generating and should not yet change practice.
AIMS: We investigated whether patients with atrial fibrillation (AF) demonstrate detectable changes in biomarkers including high-sensitivity troponin T (hsTnT), N-terminal B-type natriuretic peptide (NT-proBNP), and growth differentiation factor-15 (GDF-15) over 12 months and whether such changes from baseline to 12 months are associated with the subsequent risk of stroke or systemic embolic events (S/SEE) and bleeding. METHODS AND RESULTS: ENGAGE AF-TIMI 48 was a randomized trial of the oral factor Xa inhibitor edoxaban in patients with AF and a CHADS2 score of ≥2. We performed a nested prospective biomarker study in 6308 patients, analysing hsTnT, NT-proBNP, and GDF-15 at baseline and 12 months. hsTnT was dynamic in 46.9% (≥2 ng/L change), NT-proBNP in 51.9% (≥200 pg/mL change), GDF-15 in 45.6% (≥300 pg/mL change) during 12 months. In a Cox regression model, upward changes in log2-transformed hsTnT and NT-proBNP were associated with increased risk of S/SEE [adjusted hazard ratio (adj-HR) 1.74; 95% confidence interval (CI) 1.36-2.23 and adj-HR 1.27; 95% CI 1.07-1.50, respectively] and log2-transformed GDF-15 with bleeding (adj-HR 1.40; 95% CI 1.02-1.92). Reassessment of ABC-stroke (age, prior stroke/transient ischaemic attack, hsTnT, and NT-proBNP) and ABC-bleeding (age, prior bleeding, haemoglobin, hsTnT, and GDF-15) risk scores at 12 months accurately reclassified a significant proportion of patients compared with their baseline risk [net reclassification improvement (NRI) 0.50; 95% CI 0.36-0.65; NRI 0.42; 95% CI 0.33-0.51, respectively]. CONCLUSION: Serial assessment of hsTnT, NT-proBNP, and GDF-15 revealed that a substantial proportion of patients with AF had dynamic values. Greater increases in these biomarkers measured over 1 year are associated with important clinical outcomes in anticoagulated patients with AF.
No takes yet. Share an insight, caveat, or question.
Oyama et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: